The current state of drug discovery is inefficient and expensive. It takes an average of 12 years and $2.6 billion to bring a new drug to market.
This is due in part to the fact that drug discovery is largely a trial-and-error process. Researchers must first identify a target gene, then develop a drug that can modulate that gene's expression. This process is often time-consuming and expensive, and it can be difficult to predict which drugs will be effective.
Combinatorial Genomics.
Cognit focuses on Functional, Regulatory, and Epigenomics to enable gene expression prediction and engineering.
The Gene expression prediction platform takes any DNA sequence (DNASE) across any cell/tissue type and eukaryotes. It can predict the gene expression and transcriptomic profile of the gene across cell types.
Cognit's AI can predict gene expressions given mutations in distal regulatory elements that can be 2MB from the loci.
Cognit's perturbative oracle allows rapid CRISPR-like experiments in-silico, enabling gene expression engineering.
In-silico saturation mutagenesis experiments with gene knock-out and engineered mutations across introns, exons, and regulatory elements to predict gene expression.
Gene expression is helpful in identifying a disease's molecular signature and correlating a pharmacodynamic marker with the dose-dependent cellular responses to the exposure to a drug.
Cognit Edge
High-Resolution Genomics: We've transcended traditional views, achieving significant insights into genetic interactions.
Holistic Tumor Analysis: Our integrated approach offers a comprehensive view of tumor biology, predicting behavior with precision.
Targeted Therapies: We're identifying and validating therapeutic targets with high accuracy.
Combatting Drug Resistance: Our strategies forecast and counteract drug resistance, ensuring sustained efficacy.
Streamlined Drug Development: Efficiency and cost-effectiveness are at the heart of our optimized processes.
Personalized Therapies: Tailoring treatments to individual tumor profiles is now a reality.
Synthetic Lethality: We've identified gene combinations for enhanced tumor cell eradication.
Decoding the Genome: Illuminating previously unknown genomic regions, we're broadening our understanding of tumorigenesis.
Safety Assured: Predicting and validating off-target effects, we prioritize patient safety.
Predicting Tumor Evolution: Our tools simulate tumor evolution, keeping us steps ahead.
Revolutionized Clinical Trials: Our data-driven approach is setting new standards for trial success.